Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
CSL Behring to Acquire Biotech Company Vitaeris
Details : With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition